# Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells

> **NCT05744037** · PHASE2 · UNKNOWN · sponsor: **The Affiliated Hospital of Xuzhou Medical University** · enrollment: 30 (estimated)

## Conditions studied

- B-cell Non Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** regimen with BTK inhibitor +Anti-CD19 CAR T cells

## Key facts

- **NCT ID:** NCT05744037
- **Lead sponsor:** The Affiliated Hospital of Xuzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05744037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05744037, "Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05744037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*